Atopic Dermatitis/Atopic Eczema | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2018
Atopic dermatitis (AD) is a chronic, pediatric-onset, inflammatory skin disease marked principally by pruritus and eczema. Topical agents (e.g., corticosteroids) are the mainstays of prescription AD treatment, and systemic immunomodulators may be used to treat topical-refractory cases, although risk-averse pediatricians may avoid more-potent medications. Recent entrants from Pfizer (i.e., Eucrisa) and Sanofi/Regeneron (i.e., Dupixent) offer a new, nonsteroidal topical option and a biologic for topical-refractory adult patients, respectively. This content explores how new therapies have fared in pediatric patients and provides context for new players seeking to capitalize on the unmet needs in AD.
QUESTIONS ANSWERED
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed pediatric AD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric AD patients?
- How have Dupixent and Eucrisa been integrated into the treatment algorithm?
- What proportion of pediatric AD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of pediatric AD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated pediatric patients with AD?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
GEOGRAPHIES
- United States
REAL-WORLD DATA
Longitudinal patient-level claims data analysis
KEY DRUGS COVERED
Dupixent, Eucrisa, Protopic, Elidel, cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, key topical corticosteroids
KEY ANALYSIS PROVIDED
- Brand use across a longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.
